Thalidomide is more efficient than sodium butyrate in enhancing GATA-1 and EKLF gene expression in erythroid progenitors derived from HSCs with β-globin gene mutation
-
Mohammad Ali Jalali Far
,
Ali Dehghani Fard
,
Saiedeh Hajizamani
,
Majid Mossahebi-Mohammadi
,
Hamid Yaghooti
,
Najmaldin Saki
Abstract
Background: Efficient induction of fetal hemoglobin (HbF) is considered as an effective therapeutic approach in beta thalassemia. HbF inducer agents can induce the expression of γ-globin gene and produce high levels of HbF via different epigenetic and molecular mechanisms. Thalidomide and sodium butyrate are known as HbF inducer drugs.
Material and methods: CD133+ stem cells were isolated from umbilical cord blood of a newborn with minor β-thalassemia in order to evaluate the effects of these two drugs on the in vitro expression of GATA-1 and EKLF genes as erythroid transcription factors. CD133+ stem cells were expanded and differentiated into erythroid lineage, and then treated with thalidomide and sodium butyrate and finally analyzed by quantitative real-time PCR. Statistical analysis was performed using student’s t-test by SPSS software.
Results: Thalidomide and sodium butyrate increased GATA-1 and EKLF gene expression, compared to the non-treated control (P<0.05).
Conclusion: Thalidomide was more efficient than sodium butyrate in augmenting expression of GATA-1 and EKLF genes. It seems that GATA-1 and EKLF have crucial roles in the efficient induction of HbF by thalidomide.
Farshdousti Hagh M, Dehghani Fard A, Saki N, et al. Molecular Mechanisms of hemoglobin F induction. Int J Hematol Ooncol Stem Cell Res. 2011; 5(4):5-9.
Thein SL. Pathophysiology of beta thalassemia – a guide to molecular therapies. Hematology Am Soc Hematol Educ Program. 2005: 31–37.
Saki N, Dehghani Fard A, Kaviani S, et al. Beta thalassemia: Epidemiology, diagnostic and treatment approach in Iran. Genetics in the 3rd millennium.
Dehghani Fard A, Kaviani S, Saki N, et al. The emerging role of immunomodulatory agents in fetal hemoglobin induction. Int J Hematol Ooncol Stem Cell Res. 2012; 6(4):35-36.
Fathallah H, Taher A, Bazarbachi A, et al. Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease. Blood Cells Mol Dis. 2009; 43(1):58-62.
Aerbajinai W, Zhu J, Gao Z, et al. Thalidomide induces -globin gene expression through increased reactive oxygen species–mediated p38 MAPK signaling and histone H4 acetylation inadult erythropoiesis. Blood. 2007; 110(8):2864-71.
Moutouh-de Parseval LA, Verhelle D, Glezer E, et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34 cells. J Clin Invest. 2008; 118(1):248-58.
De Simone J, Heller P, Hall L, et al. 5-Azacytidine stimulatesfetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci. 1982; 79(14):4428-31.
DeSimone J, Koshy M, Dorn L, et al. Maintenance of elevated fetal hemoglobin levels by decitabine duringdose interval treatment of sickle cell anemia. Blood. 2002; 99(11):3905-8.
Fathallah H, Weinberg RS, Galperin Y, et al. Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin. Blood. 2007; 110(9):3391-97.
Thein SL. The emerging role of fetal hemoglobin induction in non-transfusion-dependent Thalassemia. Blood Rev. 2012; 26:35–39.
Atashi A, Soleymani M, Kaviani S, et al. In vitro induction of fetal hemoglobin in erythroid cells derived from CD133+ cells by transforming growth factor and stem cell factor. Iran J Biotechnol 2008; 6(3): 157-63.
Stamatoyannopoulos G. Control of globin gene expression during development and erythroid differentiation. Exp Hematol. 2005 Mar; 33(3):259-71.
Stopka T, Amanatullah DF, Papetti M, et al. PU.1 inhibits the erythroid program by binding to GATA-1 on DNA and creating a repressive chromatin structure. EMBO J. 2005 Nov 2;24(21):3712-23.
Dehghani Fard A, Kaviani S, Noruzinia M, et al. Synergistic effect of sodium butyrate and thalidomide in the induction of fetal hemoglobin expression in erythroid progenitors derived from CD133+ cells. Zahedan J Res Med Sci (ZJRMS). 2012;14(7):29-33.
Ahmadvand M, Noruzinia M, Soleimani M, et al. In vitro induction of gamma globin gene in erythroid cells derived from CD133+ by thalidomide and sodium butyrate. Genetics in the 3rd millennium 2011; 9(2): 2373-8.
Dehghani Fard A, Kaviani S, Noruzinia M, et al. Evaluation the Effect of Thalidomide and Sodium Butyrate on Cord Blood Stem Cell Differentiation Induction to Erythroid Lineage. Genetics in the 3rd millennium 2011; 9(3): 2457-61.
Dehghani Fard A, Kaviani S, Noruzinia M, et al. Evaluation of H3 Histone Methylation and Colony Formation in Erythroid Progenitors Treated with Thalidomide and Sodium Butyrate. Lab Hematol. 2013; 19(1):1-5.
Dehghani Fard A, Kaviani S, Noruzinia M, et al. Epigenetic modulation on fetal hemoglobin induction. Hematol Ooncol Stem Cell Res. 2012; 6(1): 11-12.
| Files | ||
| Issue | Vol 10, No 1 (2016) | |
| Section | Articles | |
| Keywords | ||
| Fetal hemoglobin Thalidomide Sodium butyrate β-thalassemia | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
